Literature DB >> 8088831

Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.

R Kaul1, K Balamurugan, G P Gao, R Matalon.   

Abstract

Canavan disease, or spongy degeneration of the brain, is a severe leukodystrophy caused by the deficiency of aspartoacylase (ASPA). Recently, a missense mutation was identified in human ASPA coding sequence from patients with Canavan disease. The human ASPA gene has been cloned and found to span 29 kb of the genome. Human aspartoacylase is coded by six exons intervened by five introns. The exons vary from 94 (exon III) to 514 (exon VI) bases. The exon/intron splice junction sites follow the gt/ag consensus sequence rule. Southern blot analysis of genomic DNA from human/mouse somatic cell hybrid cell lines localized ASPA to human chromosome 17. The human ASPA locus was further mapped in the 17p13-ter region by fluorescence in situ hybridization. The bovine aspa gene has also been cloned, and its exon/intron organization is identical to that of the human gene. The 500-base sequence upstream of the initiator ATG codon in the human gene and that in the bovine gene are 77% identical. Human ASPA coding sequences cross-hybridize with genomic DNA from yeast, chicken, rabbit, cow, dog, mouse, rat, and monkey. The specificity of cross-species hybridization of coding sequences suggests that aspartoacylase has been conserved during evolution. It should now be possible to identify mutations in the noncoding genomic sequences that lead to Canavan disease and to study the regulation of ASPA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8088831     DOI: 10.1006/geno.1994.1278

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  14 in total

1.  The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.

Authors:  O N Elpeleg; A Shaag
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 2.  Biochemistry and molecular biology of Canavan disease.

Authors:  R Matalon; K Michals-Matalon
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

3.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.

Authors:  R Kaul; G P Gao; R Matalon; M Aloya; Q Su; M Jin; A B Johnson; R B Schutgens; J T Clarke
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 4.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

5.  Molecular characterisation and prenatal diagnosis of Asparto-acylase deficiency (Canavan disease)--report of two novel and two known mutations from the Indian subcontinent.

Authors:  Sunita Bijarnia; Sudha Kohli; Ratna Dua Puri; Rintu J Jacob; Renu Saxena; Anil Jalan; Eric A Sistermans; Saqib Mahmood; Ishwar Chander Verma
Journal:  Indian J Pediatr       Date:  2012-08-10       Impact factor: 1.967

6.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

7.  Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population.

Authors:  D Kronn; C Oddoux; J Phillips; H Ostrer
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

8.  Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity--a short report.

Authors:  Hye Rim Oh; Chang Hyeok An; Nam Jin Yoo; Sug Hyung Lee
Journal:  Cell Oncol (Dordr)       Date:  2014-12-02       Impact factor: 6.730

Review 9.  Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.

Authors:  M H Baslow; T R Resnik
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

10.  Canavan disease: mutations among Jewish and non-Jewish patients.

Authors:  R Kaul; G P Gao; M Aloya; K Balamurugan; A Petrosky; K Michals; R Matalon
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.